Validation of the MCK model for predicting outcomes in myopathy-associated interstitial lung disease: a multicentre MYKO cohort study
Modern Rheumatology · 22.12.2025 · 36 (1) · 59-67
DOI: 10.1093/mr/roaf070 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Modern Rheumatology, online erschienen am 24.07.2025. Verfasst von Hirofumi Miyake und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine, Tenri Hospital, Tenri, Nara, Japan. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Myositis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To validate the MCK model’s prognostic utility in patients with idiopathic inflammatory myopathy (IIM)-associated interstitial lung disease (ILD).
Methods
This retrospective study included 242 patients with IIM-associated ILD from the multicentre MYKO cohort. Patients were classified as anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive or antibody-negative. The MCK score was defined by the number of criteria met: C-reactive protein (CRP) ≥ 0.8 mg/dL and Krebs von den Lungen 6 (KL-6) ≥ 1000 U/ml for MDA5-positive patients; CRP ≥ 1.1 mg/dL and KL-6 ≥ 1000 U/ml for MDA5-negative patients. Outcomes included all-cause mortality, disease flares, and infections requiring hospitalisation, which were assessed via Kaplan–Meier and Cox regression analyses.
Results
Amongst MDA5-positive patients, an MCK score of 2 did not significantly predict mortality. However, in MDA5-negative patients, an MCK score of 2 was significantly associated with an increased risk of all-cause mortality, disease flares, and infections requiring hospitalisation. Subgroup analyses from 2018 onward showed similar patterns, although statistical significance was not maintained.
Conclusions
The MCK model demonstrates strong predictive performance for all-cause mortality and disease complications, particularly in patients with MDA5-negative IIM. However, its predictive utility may have declined in recent years, possibly due to advancements in treatment approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Internal Medicine, Tenri Hospital, Tenri, Nara, Japan.
- Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan.
- Department of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
ORCID-Profile: Hirofumi Miyake
Zitieren
APA
Miyake, H., Nakashima, R., Tsuji, H., Sasai, T., Nohda, Y., Yoshida, T., Nakayama, Y., Nakakubo, Y., Ogawa, A., Yoshida, K., Hirobe, K., Aitani, Y., Koshida, Y., Akiyama, C., Yamamoto, M., Oe, K., Matsuda, S., Suzuka, T., & Kotani, T. (2025). Validation of the MCK model for predicting outcomes in myopathy-associated interstitial lung disease: a multicentre MYKO cohort study. Modern Rheumatology, 36(1), 59-67. https://doi.org/10.1093/mr/roaf070
Vancouver
Miyake H, Nakashima R, Tsuji H, Sasai T, Nohda Y, Yoshida T, et al. Validation of the MCK model for predicting outcomes in myopathy-associated interstitial lung disease: a multicentre MYKO cohort study. Modern Rheumatology. 2025;36(1):59-67. doi:10.1093/mr/roaf070
BibTeX
@article{Miyake2025,
author = {Miyake, Hirofumi and Nakashima, Ran and Tsuji, Hideaki and Sasai, Tsuneo and Nohda, Yasuhiro and Yoshida, Tsuneyasu and Nakayama, Yoichi and Nakakubo, Yuto and Ogawa, Atsubumi and Yoshida, Kazuma and Hirobe, Keisuke and Aitani, Yuki and Koshida, Yudai and Akiyama, Chifumi and Yamamoto, Mahiro and Oe, Katsumasa and Matsuda, Shogo and Suzuka, Takayasu and Kotani, Takuya},
title = {Validation of the MCK model for predicting outcomes in myopathy-associated interstitial lung disease: a multicentre MYKO cohort study},
journal = {Modern Rheumatology},
year = {2025},
volume = {36},
number = {1},
pages = {59--67},
doi = {10.1093/mr/roaf070}
}
EUVIMED